Paper40419987
Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
Lv M and 2 others. BMC Gastroenterol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis. Papers, record 40419987. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40419987
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Synbiotics | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Heart Disease Risk Factors | Major topic |
| Cardiovascular Diseases | Major topic |
| Humans | |
| Blood Pressure | |
| Lipids | |
| Randomized Controlled Trials as Topic | |
| Waist Circumference |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28250783 | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. | J Res Med Sci | 2016 | https://conductscience.org/library/papers/28250783 | PubMed |
| 2 | 32859329 | The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. | Clin Nutr ESPEN | 2020 | https://conductscience.org/library/papers/32859329 | PubMed |
| 3 | 35981707 | Probiotic therapy, a novel and efficient adjuvant approach to improve glycemic status: An umbrella meta-analysis. | Pharmacol Res | 2022 | https://conductscience.org/library/papers/35981707 | PubMed |
| 4 | 31009401 | The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. | Eur J Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31009401 | PubMed |
| 5 | 29931231 | Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. | J Nutr | 2018 | https://conductscience.org/library/papers/29931231 | PubMed |
| 6 | 31547555 | Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors. | Nutrients | 2019 | https://conductscience.org/library/papers/31547555 | PubMed |
| 7 | 33259835 | The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | Metabolism | 2021 | https://conductscience.org/library/papers/33259835 | PubMed |
| 8 | 29584449 | Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. | Crit Rev Food Sci Nutr | 2019 | https://conductscience.org/library/papers/29584449 | PubMed |
| 9 | 34725349 | Synbiotic (Lactiplantibacillus pentosus GSSK2 and isomalto-oligosaccharides) supplementation modulates pathophysiology and gut dysbiosis in experimental metabolic syndrome. | Sci Rep | 2021 | https://conductscience.org/library/papers/34725349 | PubMed |
| 10 | 37111082 | Effect of a Multispecies Synbiotic Supplementation on Body Composition, Antioxidant Status, and Gut Microbiomes in Overweight and Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. | Nutrients | 2023 | https://conductscience.org/library/papers/37111082 | PubMed |
| 11 | 22190648 | Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. | Diabetes | 2012 | https://conductscience.org/library/papers/22190648 | PubMed |
| 12 | 7786990 | Operating characteristics of a rank correlation test for publication bias. | Biometrics | 1994 | https://conductscience.org/library/papers/7786990 | PubMed |
| 13 | 36908920 | Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis. | Front Nutr | 2023 | https://conductscience.org/library/papers/36908920 | PubMed |
| 14 | 33987427 | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | Ann Transl Med | 2021 | https://conductscience.org/library/papers/33987427 | PubMed |
| 15 | 35795187 | The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35795187 | PubMed |
| 16 | 37388120 | The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis. | Ther Adv Gastroenterol | 2023 | https://conductscience.org/library/papers/37388120 | PubMed |
| 17 | 38694388 | Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/38694388 | PubMed |
| 18 | 38729941 | The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. | Nutr Diabetes | 2024 | https://conductscience.org/library/papers/38729941 | PubMed |
| 19 | 28345499 | Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. | Br J Nutr | 2017 | https://conductscience.org/library/papers/28345499 | PubMed |
| 20 | 32322969 | Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials. | Eur J Nutr | 2020 | https://conductscience.org/library/papers/32322969 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42311765 | Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42311765 | PubMed |
| 41902532 | Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/41902532 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40419987
GET https://conductscience.org/api/papers/v1/40419987/references?page=2